A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH2722 Injection Combined With Background Therapy in Patients With Seasonal Allergic Rhinitis
Latest Information Update: 09 Jan 2025
Price :
$35 *
At a glance
- Drugs TQH 2722 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 09 Jan 2025 New trial record